Bensmail D, Vermersch P
Service de Médecine Physique et Réadaptation, Hôpital R Poincaré, AP-HP, EA 4497, Université de Versailles-Saint-Quentin, 104 Bd R. Poincaré, 92380 Garches, France.
Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S45-50. doi: 10.1016/S0035-3787(12)70046-2.
Spasticity is a commonly seen symptom in patients with multiple sclerosis (MS). The vast majority of patients will suffer from this symptom during the course of the disease, and one- third of patients considers that spasticity contributes to a greater part of their disability. The symptom is frequently disabling. It can, however, allow some activities to be performed. Treatment of the symptom is sometimes deleterious, which is why strict assessment of the consequences of spasticity and anticipation of the outcome of antispastic treatment are necessary. Clinical scales, such as the Ashworth and Tardieu scales, are used in clinical practice. The essential element is not, however, assessment of the symptom, but its repercussions on activities of everyday life. It is important to make a list of what patients consider to be disabling situations to verify that they are truly consequences of spasticity. Considering the heterogeneity of clinical expression of spasticity in patients with MS, the use of a scale such as goal attainment scaling (GAS) can probably be totally adapted for the assessment of the effects of antispastic treatment.
痉挛是多发性硬化症（MS）患者常见的症状。绝大多数患者在疾病过程中会出现这种症状，三分之一的患者认为痉挛是其残疾的主要原因。该症状常常导致残疾。然而，它也能使一些活动得以进行。对该症状的治疗有时是有害的，这就是为什么必须严格评估痉挛的后果并预测抗痉挛治疗的结果。临床实践中使用如Ashworth和Tardieu量表等临床量表。然而，关键要素不是对症状的评估，而是其对日常生活活动的影响。列出患者认为导致残疾的情况很重要，以核实它们是否真的是痉挛的后果。考虑到MS患者痉挛临床表现的异质性，使用目标达成量表（GAS）等量表可能完全适用于评估抗痉挛治疗的效果。
